Elegen launches Enfina DNA enhancement for rapid synthesis of highly complex DNA
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Acquisition of exclusive commercialization rights for European markets
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The product will be launched in March 2024
Subscribe To Our Newsletter & Stay Updated